Feed / HALO

Halozyme Therapeutics, Inc.

HALO

Healthcare · 108.14 +1.9% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Halozyme Therapeutics, Inc.'s move is being confirmed by its market group.

HALO accounts for 1.6% of the group's measured movement across 7.8 effective names. raw member direction is mixed; 6 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 41%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveCounter-move#10 of 12 by movement share
Group movement share1.6%Absolute path energy—not portfolio weight
Relative path+0.11%counter
Effective breadth7.8 / 12broad
Relative alignment6/12downside path · 4 counter-moving
Capital-flow agreement41%not yet clean
SEQUENCE READ

NBIX, BMRN, REGN moved materially before HALO. HALO crossed its material path threshold at 14:00 ET, 200 minutes after the first measured mover.

What changed
  • Revenue increased 42.2% versus the comparable filing period.
  • Operating margin fell 4.5 percentage points.
EVIDENCE COVERAGE

8 of 15 members in Biopharmaceuticals and Care are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 10 of 15 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ABBV begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.

Watch this read

Who this business touches

The relationships behind HALO

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

TEVATeva Pharmaceutical Industries LimitedsupplierMay 11, 2026 ▾

“We have commercialized auto-injector products with Teva Pharmaceutical Industries, Ltd.”

PFEPfizer, Inc.partnerMay 11, 2026 ▾

“13 Table of Contents Pfizer Collaboration In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprieta…”

Depended on by

ORKAOruka Therapeutics, Inc.partnerMay 13, 2026 ▾

“On May 1, 2026, the Company and Halozyme Hypercon, Inc.”

Filing peers

ABBVINVAZYME

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 21 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

HALO is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.